Cholinergic-specific glycoconjugates.
Cholinergic nerve terminals utilize glycoconjugates in several ways, as surface markers and as structural components of the synaptic vesicles present within them. The surface markers have been discovered immunochemically: antibodies raised against them are able specifically to sensitize the cholinergic subpopulation of mammalian brain synaptosomes to complement-mediated lysis. One such group of antigens (Chol-1) have been identified as a novel series of minor gangliosides having in common a sialylated N-acetylgalactosamine residue. These gangliosides may constitute the major gangliosides at cholinergic terminals. A second surface antigen (Chol-2) is thought to be a protein with an epitope in common with a Torpedo electric organ ganglioside. Cholinergic synaptic vesicles are rich in a proteoglycan which appears to assist in the sequestration of acetylcholine within the vesicle and to stabilize the vesicle membrane during cycles of exocytosis and recovery. It may be the cholinergic equivalent of the chromogranins.
Whittaker
V P
VP
Max-Planck-Institut für Biophysikalische Chemie, Göttingen, FR Germany.
Kelić
S
S
D000954:Antigens, Surface / Q000276:immunology*; D018678:Cholinergic Agents / Q000276:immunology*; D000939:Epitopes; D005732:Gangliosides / Q000276:immunology*; D006001:Glycoconjugates / Q000276:immunology*; D006801:Humans; D007150:Immunohistochemistry; D009024:Morphogenesis; D009411:Nerve Endings / Q000276:immunology*; D013569:Synapses / Q000276:immunology
D000954:Antigens, Surface; D018678:Cholinergic Agents; D000939:Epitopes; D005732:Gangliosides; D006001:Glycoconjugates; C038777:chol-1 antigen